141109-16-2

Basic information

• Product Name: (R)-(-)-2-CHLOROPHENYLGLYCINE METHYL ESTER
• Synonyms: (R)-(-)-2-CHLOROPHENYLGLYCINE METHYL ESTER;Benzeneacetic acid, a-aMino-2-chloro-, Methyl ester, (aR)-
• CAS NO: 141109-16-2
• Molecular Formula: C₉H₁₀ClNO₂
• Molecular Weight: 199.63
• Product Categories: chiral
• Mol File: 141109-16-2.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 270.097 °C at 760 mmHg
• Flash Point: 117.151 °C
• Appearance: /
• Density: 1.258 g/cm³
• Vapor Pressure: 0.007mmHg at 25°C
• Refractive Index: 1.551
• Solubility: Acetonitrile (Slightly), Chloroform (Slightly), DMSO (Slightly), Methanol (Sligh
• CAS DataBase Reference: (R)-(-)-2-CHLOROPHENYLGLYCINE METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-(-)-2-CHLOROPHENYLGLYCINE METHYL ESTER(141109-16-2)
• EPA Substance Registry System: (R)-(-)-2-CHLOROPHENYLGLYCINE METHYL ESTER(141109-16-2)

Safety Data

• Hazardous Substances Data: 141109-16-2(Hazardous Substances Data)

Usage

General Description

"(R)-(-)-2-Chlorophenylglycine Methyl Ester is a synthetic chemical compound often used in pharmaceutical and chemical research. It is a type of non-proteinogenic amino acid, meaning it is not directly involved in coding for DNA but can be used in the biosynthesis of secondary metabolites. Importantly, this compound can be utilized as a starting material for the synthesis of a variety of significant bioactive molecules. It is noteworthy that "(R)-(-)-2-Chlorophenylglycine Methyl Ester" refers to the specific structure of the molecule, indicating its configuration in three-dimensional space. Chemical safety and handling precautions should be followed when dealing with this or any other similar compound.

InChI:InChI=1/C9H10ClNO2/c1-13-9(12)8(11)6-4-2-3-5-7(6)10/h2-5,8H,11H2,1H3/t8-/m1/s1

Upstream product

• 1233361-76-6 L-(+)-tartaric acid salt of α-amino-(2-chlorophenyl)acetic acid methyl ester 
• 67-56-1 methanol 
• 86169-24-6 2-amino-(2-chlorophenyl)ethanoic acid 
• 1253091-76-7 methyl 2-((tert-butoxycarbonyl)amino)-2-(2-chlorophenyl)acetate 
• 141109-14-0 2-(2-chlorophenyl)glycine methyl ester hydrochloride 

Downstream Products

• 92233-02-8 (Ethoxycarbonyl)-4 (o-chlorophenyl)-2 methyl-3 aza-3 butanoate de methyle 
• 1001414-68-1 (R)-(-)-methyl 2-(tert-butoxycarbonylamino)-2-(2-chlorophenyl)acetate 
• 532986-40-6 N-[1-(2-chlorophenyl)-2-hydroxyethyl]octanamide 
• 92233-10-8 Acide (o-chlorophenyl)-2 methyl-4 aza-3 pentanedioique-1,5 
• 141109-18-4 methyl [2-(thien-2-yl)ethylamino](2-chlorophenyl)-acetate hydrochloride 
• 141109-15-1 2-chlorophenylglycine methyl ester L-(+)-tartaric acid 
• 1227294-00-9 (2S,3S,3aS,9bS)-3-ethyl-2-methyl-2-(2-chlorophenyl)-1,2,3,3a,4,9b-hexahydrochromeno[4,3-b]pyrrole-2,3-dicarboxylate 
• 1276118-81-0 C₁₆H₁₄ClNO₂ 
• 1276118-73-0 C₁₁H₁₃ClN₂O 
• 1276118-74-1 C₁₂H₁₅ClN₂O 
• 1276118-75-2 C₁₃H₁₇ClN₂O 
• 1313411-65-2 C₁₉H₁₇ClN₂O₂ 
• 1276118-82-1 C₁₂H₁₃ClN₂O₂ 
• 1276118-83-2 C₁₉H₁₉ClN₂O₃ 

Relevant articles and documents

Preparation method of clopidogrel hydrogen sulfate intermediate

The present invention relates to a preparation method of a clopidogrel hydrogen sulfate intermediate. (+)-2-chlorophenylglycine methyl ester and alpha-thiopheneethanol p-toluenesulfonate are adopted as raw materials, a reaction solvent and an acid-binding agent are added for a condensation reaction, the condensation reaction process is divided into a first stage and a second stage, and when 60-95% of the condensation reaction is completed, first-stage reaction is completed; after the first-stage reaction is completed, firstly part of the reaction solvent is removed, and then second-stage reaction is carried out; and after the second-stage reaction is completed, a target product is obtained, namely the clopidogrel hydrogen sulfate intermediate. After the first-stage reaction is completed, part of the reaction solvent is removed firstly, and then the second-stage reaction is continued, so that the concentration of the reaction material can be increased in the later stage of the condensation reaction, the use amount of the reaction solvent is reduced, and racemization and side reaction in the reaction process are effectively inhibited, thereby improving the chiral purity of the product, increasing the yield, reducing the use of auxiliary materials greatly, and reducing the production cost.

Preparation method of sulfonic clopidogrel impurity

The invention discloses a preparation method of a sulfonic clopidogrel impurity. The preparation method comprises the following steps: reacting thiophene-2-ethanol with toluenesulfonyl chloride to generate p-toluenesulfonic acid-2-thienylethyl ester; carrying out esterification on o-chlorophenylglycine and methanol to generate o-chlorophenylglycine methyl ester; resolving the o-chlorophenylglycinemethyl ester by using L(+) tartaric acid; converting into free S-(+)-o-chlorophenylglycine methyl ester in dichloromethane; carrying out a condensation reaction on the p-toluenesulfonic acid-2-thienylethyl ester and the S-(+)-o-chlorophenylglycine methyl ester under an alkaline condition; acidifying the obtained product to generate (S)-2-(2-thienylethylamino)(2-chlorphenyl)methyl acetate, carrying out a condensation reaction on the (S)-2-(2-thienylethylamino)(2-chlorphenyl)methyl acetate and formaldehyde to obtain clopidogrel, and carrying out a reaction on the clopidogrel and chlorosulfonicacid to generate sulfonic clopidogrel impurity. The preparation method of the sulfonic clopidogrel impurity has the advantages of mild reaction conditions, accessible raw materials, low cost and highyield and purity.

A compound clopidogrel hydrogensulfate method for the preparation of

The invention relates to a preparation method of clopidogrel disulfate. The preparation method comprises the following steps of step one. carrying out esterification reaction, namely preparing (+/-) DL-2-Chlorophenylglycine methyl ester; step two. carrying out splitting reaction, namely preparing (+) DL-2-Chlorophenylglycine methyl ester; step three. carrying out activating reaction, namely preparing alpha-thiophene ethanol p-toluenesulfonates; step four. carrying out substitution reaction, namely preparing (+) alpha-(2-thiophene ethylamino)-2-(2-chlorobenzene) methyl acetate hydrochloride; step five. carrying out ring closing reaction, namely preparing clopidogrel; and step six. carrying out salt-forming reaction, namely preparing the clopidogrel disulfate. The preparation method has the advantages that the preparation technology is optimized and improved, reaction conditions are mild, the splitting and the racemization are truly and synchronously carried out, and an obtained crude product has high specific rotation; a catalyst is used in the substitution reaction, so that the reaction time is shortened; the ring closing reaction is carried out at 40 DEG C under the condition of avoiding light, so that the purity of the product is relatively high; and the period of the whole synthetic route is shortened, the aftertreatment operation is simple, and therefore, the preparation method is suitable for mass production.